欧林生物：谭勇和吴畏计划减持公司股份分别不超过约12.89万股和17.85万股

Group 1 - The company, Olin Bio, announced that as of the disclosure date, its financial officer and deputy general manager, Mr. Tan Yong, holds approximately 570,000 shares, accounting for 0.14% of the total share capital [1] - Mr. Tan plans to reduce his holdings by up to approximately 128,900 shares, while the company’s board secretary and deputy general manager, Mr. Wu Wei, holds about 778,400 shares, representing 0.19% of the total share capital [1] - Mr. Wu also intends to reduce his holdings by up to approximately 178,500 shares within three months after the announcement of the reduction plan [1] Group 2 - For the year 2024, Olin Bio's revenue composition is primarily from the pharmaceutical manufacturing industry, which accounts for 99.53% of total revenue, with other businesses making up 0.47% [2] - The current market capitalization of Olin Bio is 11.1 billion yuan [3]